CY
CY9D.F Microbot Medical Inc
- Market cap
- EUR 62.5M
- P/E
- -
- P/B
- 1.07x
- ROE
- -27.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CY9D.F undervalued?
Graham numberThe Graham number of Microbot Medical Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Microbot Medical Inc fundamental analysis
No fundamental analysis for Microbot Medical Inc yet.
Microbot Medical Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Microbot Medical Inc
Microbot Medical Inc. is a medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system designed to maneuver guidewires and over-the-wire devices, such as microcatheters within the body's vasculature for use in cardiovascular, peripheral, endovascular, and neurovascular operations. It also provides NovaCross, a…
Full company profileMicrobot Medical Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Microbot Medical Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 692K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | -1.28M |
| Operating Income | -9.64M | -5.27M | -7.24M | -7.24M | -9.09M | -11.4M | -13.3M | -10.1M | -11.6M | -14.7M | -21.0M |
| EBITDA | - | -5.25M | -7.19M | -7.06M | -9.02M | -11.3M | -13.2M | -10.0M | -11.5M | -14.7M | -21.0M |
| Net Income | -9.66M | -7.59M | -7.24M | -7.25M | -9.17M | -11.3M | -13.2M | -10.7M | -11.4M | -13.1M | -18.6M |
| EPS | - | -2.80 | -2.40 | -1.01 | -1.29 | -1.59 | -1.67 | -0.92 | -0.59 | -0.20 | -0.28 |
| Balance Sheet | |||||||||||
| Total Assets | 3.37M | 11.0M | 6.09M | 37.1M | 26.3M | 16.8M | 9.54M | 8.33M | 6.03M | 81.5M | 73.4M |
| Total Liabilities | 1.67M | 1.06M | 4.77M | 5.59M | 1.97M | 2.39M | 2.25M | 3.83M | 2.50M | 3.99M | 4.44M |
| Shareholders' Equity | 1.70M | 9.96M | 1.32M | 31.5M | 24.3M | 14.4M | 7.29M | 4.50M | 3.53M | 77.6M | 68.9M |
| Cash & Short-term Investments | 2.71M | 10.8M | 5.24M | 28.8M | 19.7M | 13.5M | 2.44M | 2.47M | 3.11M | 3.91M | 3.15M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -786K | -4.86M | -5.31M | -6.45M | -7.25M | -9.35M | -11.5M | -8.53M | -8.83M | -13.0M | -20.1M |
| Capital Expenditure | 25.0K | 58.0K | 223K | 216K | 91.0K | 69.0K | 84.0K | 33.0K | 25.0K | 60.0K | 500K |
| Free Cash Flow | - | -4.91M | -5.53M | -6.67M | -7.34M | -9.42M | -11.6M | -8.57M | -8.85M | -13.1M | -20.6M |
| Ratios | |||||||||||
| ROE | -569.8% | -76.2% | -547.7% | -23.0% | -37.7% | -78.7% | -180.7% | -238.6% | -324.2% | -16.9% | -27.0% |
| ROA | -286.9% | -68.9% | -118.9% | -19.5% | -34.9% | -67.5% | -138.1% | -129.0% | -189.7% | -16.1% | -25.3% |
| Net Profit Margin | - | - | - | - | - | - | - | - | - | - | -2,687.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Microbot Medical Inc dividends
Microbot Medical Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:15 on Sep 5, 2018.
Who owns Microbot Medical Inc
- Insiders 0.00%
- Institutions 17.71%
- Public & others 82.29%
- Shares outstanding 67.2M
- Free float 67.2M
Microbot Medical Inc company profile
- Company name
- Microbot Medical Inc
- Ticker
- CY9D.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 43
- Fiscal year end
- December
- Address
- 175 Derby Street, Hingham, MA, United States, 02043
- Phone
- 781 875 3605
- Website
- microbotmedical.com
About Microbot Medical Inc
Microbot Medical Inc. is a medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system designed to maneuver guidewires and over-the-wire devices, such as microcatheters within the body's vasculature for use in cardiovascular, peripheral, endovascular, and neurovascular operations. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system; and Emory University, in connection with autonomous robotics in endovascular procedures. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Microbot Medical Inc management
6- Mr. Harel GadotCo-Founder, President, CEO & Chairman · born 1973
- Ms. Rachel VakninChief Financial Officer · born 1979
- Dr. Simon Sharon MBA, MScCTO & GM of Microbot Israel · born 1960
- Ms. Christina BaileyVice President of Sales
- Ms. Allison RosefortVice President of Marketing
- Mr. Michael LytleHead of Sales Operations & Analytics